Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?
Uro-Oncology
Related content
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
Uro-Oncology
Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
Prostate Cancer Prostatic Dis.
Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY
doi: 10.1038/pcan.2016.58.
Uro-Oncology
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer
Prostate Cancer Prostatic Dis.
Preisser F, Gandaglia G, Arad F, Karakiewicz PI, Bandini M, Pompe RS, Montorsi F, Graefen M, Huland H, Briganti A, Tilki D
doi: 10.1038/s41391-020-00266-4.
Uro-Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI
doi: 10.1038/s41391-021-00395-4
Uro-Oncology
Systemic treatments for high-risk localized prostate cancer
Nat Rev Urol.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D
doi: 10.1038/s41585-018-0017-x.
Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology
Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade
Cancer Med.
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL
doi: 10.1002/cam4.1103.
HPV and Gynecologic Cancer
Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis
Lancet HIV.
Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P; ART and HPV Review Group
doi: 10.1016/
Uro-Oncology
Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic
Eur Urol.
Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z
doi: 10.1016/j.eururo.2020.04.063.
Further Publications Urology
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer
Prostate Cancer Prostatic Dis
Eckhardt C, Sbiera I, Krebs M, Sbiera S, Spahn M, Kneitz B, Joniau S, Fassnacht M, Kübler H, Weigand I, Kroiss M
doi: 10.1038/s41391-021-00431-3